Untitled - Roche Trasplantes

EARLY DIAGNOSIS OF CHRONIC ALLOGRAFT NEPHROPATHY
BY MEANS OF PROTOCOL BIOPSIES
43. Lee PC, Terasaki PI, Takemoto SK, Lee PH, Hung CJ, Chen YL, Tsai A, Lei HY. All chronic
rejection failures of kidney transplants were preceded by the development of HLA
antibodies. Transplantation 2002; 74: 1192-4.
44. Bohmig GA, Exner M, Habicht A, Schillinger M, Lang U, Kletzmayr J, Saemann MD, Horl
WH, Watschinger B, Regele H. Capillary C4d deposition in kidney allografts: a specific
marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091-9.
45. Jin YP, Jindra PT, Gong KW, Lepin EJ, Reed EF. Anti-class I antibodies activate endothelial
cells and promote chronic rejection. Transplantation 2005; 79: S19-S21.
46. Joosten SA, Sijpkens YWJ, van Ham V, Trouw LA, van der Vlag J, van den Heuval B, van
Kooten C, Paul LC. Antibody response against the glomerular basement membrane protein
agrin in patients with transplant glomerulopathy. Am J Transplant 2005; 5: 383-93.
47. Suri DL, Tomlanovich Sj, Olsen JL, Meyer TW. Transplant glomerulopathy as a cause
of late graft loss. Am J Kidney Dis 2000; 35: 674-680.
48. Nankivell BJ, Borrows RJ, Fung CL-S, O’Connell PJ, Allen RDMA, Chapman JR.
Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation
2004; 78: 461-8.
49. Anil Kumar MS, Moritz MJ, Saaed MI, Heifets M, Sustento-Reodica N, Fyfe B, Kumar
A. Avoidance of chronic steroid therapy in african american kidney transplant
recipients monitored by surveillance biopsy: 1-year results. Am J Transplant 2005
Aug; 5 (8): 1976-85.
50. Kee TY-S, Chapman JR, O’Connell PJ, Fung CL-S, Allen RDM, Kable K, Vitalone MJ,
Nankivell BJ. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney
transplants. Transplantation 2006; 82: 36-42.
51. Flechner SM, Friend PJ, Brockmann J, Ismail HR, Zilvetti M, Goldfarb D, Modlin C,
Mastroianni B, Savas K, Devaney A, Simmonds M, Cook DJ. Alemtuzumab induction
and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney
transplant immunosuppression. Am J Transplant 2005 Dec; 5: 3009-14.
52. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from
sirolimus-based therapy in kidney transplantation: a systematic review of randomized
trials. Am J Transplant 2005; 5: 1748-5.
53. Kaiskie JASN meta Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of
immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000;
11: 1910-7.
54. Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, Claesson K, Castagneto
M, Campistol JM, Hutchison B, Burke JT, Yilmaz S, Hayry P, Neylan JF. Rapamune
Maintenance Regimen Trial. Sirolimus-based therapy following early cyclosporine withdrawal
provides significantly improved renal histology and function at 3 years. Am J
Transplant 2004; 4: 953-61.
55. Vitlaone M, Nankivell BJ, Fung C, Wavamaundo M, Allen RDM, Pleass H, Chapman
JR, O’Connell PJ. Microarrays detect profibrotic gene expression in human renal allografts
early after transplantation associated with chronic allograft nephropathy.
Transplantation 2006, 82, WTC Abstract 1057.
29